ZIVO Bioscience (ZIVO) Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.

Do analysts prefer YMAB or ZIVO?

Y-mAbs Therapeutics currently has a consensus price target of $18.30, indicating a potential upside of 290.19%. Given Y-mAbs Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
ZIVO Bioscience	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community believe in YMAB or ZIVO?

Y-mAbs Therapeutics received 39 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. Likewise, 63.30% of users gave Y-mAbs Therapeutics an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.

Company	Underperform	Outperform
Y-mAbs Therapeutics	Outperform Votes 138 63.30%	Underperform Votes 80 36.70%
ZIVO Bioscience	Outperform Votes 99 60.74%	Underperform Votes 64 39.26%

Is YMAB or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. ZIVO Bioscience's return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-28.22%	-24.61%	-18.49%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Do institutionals and insiders hold more shares of YMAB or ZIVO?

70.8% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 22.5% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media refer more to YMAB or ZIVO?

In the previous week, Y-mAbs Therapeutics had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 0 mentions for ZIVO Bioscience. Y-mAbs Therapeutics' average media sentiment score of 0.44 beat ZIVO Bioscience's score of 0.00 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Y-mAbs Therapeutics	Neutral
ZIVO Bioscience	Neutral

Which has more risk and volatility, YMAB or ZIVO?

Y-mAbs Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.

Which has preferable earnings and valuation, YMAB or ZIVO?

ZIVO Bioscience has lower revenue, but higher earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$87.69M	2.42	-$21.43M	-$0.67	-7.00
ZIVO Bioscience	$15.85K	3,826.88	-$7.78M	-$4.28	-3.74

Summary

Y-mAbs Therapeutics beats ZIVO Bioscience on 14 of the 19 factors compared between the two stocks.